Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
ARMP US​

Armata Pharmaceuticals, Inc.(ARMP US)

$3.64+0.195.51%Ext:$3.01-0.6317.21%(Market Closed · 00:00:02 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings
CategorizedChronologicalBy Owner

SEC Filings

Financials(117)

Expand
  • 10-QQ2ended 30 Jun 202612 Aug
  • 10-QQ1ended 31 Mar 202613 May
  • 10-KFY 2025ended 31 Dec 202525 Mar
  • 10-QQ3ended 30 Sept 202512 Nov 2025
  • 10-QQ2ended 30 Jun 202512 Aug 2025
  • 10-QQ1ended 31 Mar 202514 May 2025
  • 10-KFY 2024ended 31 Dec 202421 Mar 2025
  • 10-QQ3ended 30 Sept 202413 Nov 2024
  • 10-QQ2ended 30 Jun 202413 Aug 2024
  • 10-QQ1ended 31 Mar 20247 May 2024
  • 10-KFY 2023ended 31 Dec 202321 Mar 2024
  • 10-QQ3ended 30 Sept 202314 Nov 2023
  • 10-QQ2ended 30 Jun 202314 Aug 2023
  • 10-QQ1ended 31 Mar 202311 May 2023
  • 10-KFY 2022ended 31 Dec 202216 Mar 2023

Events(324)

Expand
  • 8-KOther Events23 Sep
  • 8-KRegulation FD Disclosure14 Sep
  • 8-K​​​​​​​​​​ ​ ​June 30, 2026​ ​ ​December 31, 2025​ ​ ​Assets​​​​​​​Current assets​​​​​​​Cash and cash equivalents​$23,952​$8,688​Prepaid expenses and other current assets​673​1,508​Other receivables​​2,532​​472​Total current assets​27,157​10,668​Property and equipment, net​11,230​12,194​Operating lease right-of-use asset​32,884​33,911​Intangible assets, net​​13,746​​13,746​Other long-term assets​4,933​6,363​Total assets​$89,950​$76,882​​​​​​​​​Liabilities and stockholders’ deficit​​​​​Accounts payable, accrued and other current liabilities​$8,715​$8,947​Convertible Loan, current​​163,904​​—​Term debt, current​​77,580​​—​Total current liabilities​250,199​8,947​Convertible Loan, non-current​​—​​153,860​Term debt, non-current​​42,024​​103,061​Operating lease liabilities, net of current portion​​25,823​​26,533​Deferred tax liability​​3,077​​3,077​Total liabilities​321,123​295,478​Total stockholders’ deficit​(231,173)​(218,596)​Total liabilities and stockholders’ deficit​$89,950​$76,882​12 Aug
  • 8-KRegulation FD Disclosure20 Jul
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers20 Jul
  • 8-KRegulation FD Disclosure13 Jul
  • 8-K/ADeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers24 Jun
  • 8-KOther Events23 Jun
  • 8-KSubmission of Matters to a Vote of Security Holders16 Jun
  • 8-K​​​​​​​​​​ ​ ​March 31, 2026​ ​ ​December 31, 2025​ ​ ​Assets​​​​​​​Current assets​​​​​​​Cash and cash equivalents​$4,754​$8,688​Prepaid expenses and other current assets​1,145​1,508​Other receivables​​47​​472​Total current assets​5,946​10,668​Property and equipment, net​11,780​12,194​Operating lease right-of-use asset​33,395​33,911​Intangible assets, net​​13,746​​13,746​Other long term assets​4,933​6,363​Total assets​$69,800​$76,882​​​​​​​​​Liabilities and stockholders’ deficit​​​​​Accounts payable, accrued and other current liabilities​$9,228​$8,947​Total current liabilities​9,228​8,947​Convertible loan, non-current​​254,922​​153,860​Term debt, non-current​​87,976​​103,061​Operating lease liabilities, net of current portion​​26,183​​26,533​Deferred tax liability​​3,077​​3,077​Total liabilities​381,386​295,478​Total stockholders’ deficit​(311,586)​(218,596)​Total liabilities and stockholders’ deficit​$69,800​$76,882​13 May
  • 8-KRegulation FD Disclosure7 May
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers27 Apr
  • 8-KOther Events2 Apr
  • 8-K​​​​​​​​​​ ​ ​December 31, 2025​ ​ ​December 31, 2024​ ​ ​Assets​​​​​​​Current assets​​​​​​​Cash and cash equivalents​$8,688​$9,291​Prepaid expenses and other current assets​1,508​1,273​Other receivables​​472​​744​Total current assets​10,668​11,308​Property and equipment, net​12,194​13,241​Operating lease right-of-use asset​33,911​41,687​Intangible assets, net​​13,746​​13,746​Other long term assets​6,363​6,455​Total assets​$76,882​$86,437​​​​​​​​​Liabilities and stockholders’ deficit​​​​​Accounts payable, accrued and other current liabilities​$8,947​$9,295​Term debt, current​​—​​38,954​Total current liabilities​8,947​48,249​Convertible loan, non-current​​153,860​​32,897​Term debt, non-current​​103,061​​22,539​Operating lease liabilities, net of current portion​​26,533​​27,694​Deferred tax liability​​3,077​​3,077​Total liabilities​295,478​134,456​Total stockholders’ deficit​(218,596)​(48,019)​Total liabilities and stockholders’ deficit​$76,882​$86,437​25 Mar
  • 8-KRegulation FD Disclosure19 Mar

Insider Ownership(267)

Expand
  • 4Birx Deborah14 Jul
  • 4Gilmer Daniel B.28 Apr
  • 3Gilmer Daniel B.28 Apr
  • 4Kyme Pierre17 Mar
  • 4Birx Deborah17 Mar
  • 4Kramer Robin11 Mar
  • 4Kyme Pierre11 Mar
  • 4House David Duane11 Mar
  • 4PATTI JOSEPH M11 Mar
  • 4Peterson Todd C.11 Mar
  • 4Odysseas Kostas D11 Mar
  • 4Birx Deborah11 Mar
  • 4Schlesinger Sarah J.11 Mar
  • 4Haimovitz Jules11 Mar
  • 4Birx Deborah14 Jul 2025

Beneficial Ownership(100)

Expand
  • SC 13D/AArmata Pharmaceuticals, Inc.13 May
  • SC 13D/AArmata Pharmaceuticals, Inc.26 Jan
  • SC 13D/AArmata Pharmaceuticals, Inc.12 Aug 2025
  • SC 13D/AArmata Pharmaceuticals, Inc.12 Mar 2025
  • SC 13D/AArmata Pharmaceuticals, Inc.14 Nov 2024
  • SC 13D/AArmata Pharmaceuticals, Inc.4 Mar 2024
  • SC 13D/AArmata Pharmaceuticals, Inc.11 Jul 2023
  • SC 13D/AArmata Pharmaceuticals, Inc.10 Jan 2023
  • SC 13D/AArmata Pharmaceuticals, Inc.1 Apr 2022
  • SC 13D/AArmata Pharmaceuticals, Inc.11 Feb 2022
  • SC 13D/AArmata Pharmaceuticals, Inc.1 Nov 2021
  • SC 13D/AArmata Pharmaceuticals, Inc.5 Apr 2021
  • SC 13D/AArmata Pharmaceuticals, Inc.17 Mar 2021
  • SC 13D/AArmata Pharmaceuticals, Inc.27 Jan 2021
  • SC 13D/AArmata Pharmaceuticals, Inc.31 Mar 2020

Proxies(75)

Expand
  • ARSAnnual report to security holders27 Apr
  • DEF 14ADefinitive proxy statement27 Apr
  • ARSAnnual report to security holders28 Apr 2025
  • DEF 14ADefinitive proxy statement28 Apr 2025
  • DEF 14ADefinitive proxy statement29 Apr 2024
  • ARSAnnual report to security holders29 Apr 2024
  • DEF 14ADefinitive proxy statement3 Aug 2023
  • ARSAnnual report to security holders3 Aug 2023
  • DEFA14ADefinitive additional materials3 Aug 2023
  • PRE 14APreliminary proxy statement24 Jul 2023
  • DEF 14ADefinitive proxy statement17 Oct 2022
  • DEF 14ADefinitive proxy statement9 Mar 2022
  • PRE 14APreliminary proxy statement24 Feb 2022
  • DEFA14ADefinitive additional materials22 Apr 2021
  • DEF 14ADefinitive proxy statement21 Apr 2021

Registrations(155)

Expand
  • S-8Registration statement (employee benefit plan)10 Jul
  • 424B5Prospectus filing (Rule 424(b)(5))1 Dec 2025
  • S-8Registration statement (employee benefit plan)13 Aug 2025
  • S-3Registration statement (primary offering)13 Aug 2025
  • S-8Registration statement (employee benefit plan)23 Jan 2024
  • S-8Registration statement (employee benefit plan)15 Nov 2023
  • 424B3Prospectus filing (Rule 424(b)(3))6 Apr 2023
  • S-3/ARegistration statement (primary offering, amendment)28 Mar 2023
  • S-3Registration statement (primary offering)13 Feb 2023
  • 424B3Prospectus filing (Rule 424(b)(3))1 Jun 2022
  • S-3/ARegistration statement (primary offering, amendment)24 May 2022
  • S-3Registration statement (primary offering)16 May 2022
  • 424B3Prospectus filing (Rule 424(b)(3))6 Apr 2022
  • S-3Registration statement (primary offering)29 Mar 2022
  • 424B3Prospectus filing (Rule 424(b)(3))20 May 2021

Filing Review Correspondence(24)

Expand
  • CORRESPFiling review correspondence20 Aug 2025
  • CORRESPFiling review correspondence7 Nov 2023
  • CORRESPFiling review correspondence5 Apr 2023
  • CORRESPFiling review correspondence26 May 2022
  • CORRESPFiling review correspondence5 Apr 2022
  • CORRESPFiling review correspondence18 May 2021
  • CORRESPFiling review correspondence22 Feb 2021
  • CORRESPFiling review correspondence6 Apr 2020
  • CORRESPFiling review correspondence6 Apr 2020
  • CORRESPFiling review correspondence9 Oct 2018
  • CORRESPFiling review correspondence9 Oct 2018
  • CORRESPFiling review correspondence4 May 2017
  • CORRESPFiling review correspondence4 May 2017
  • CORRESPFiling review correspondence4 May 2017
  • CORRESPFiling review correspondence4 May 2017

SEC Orders And Notices(34)

Expand
  • EFFECTNotice of effectiveness22 Aug 2025
  • EFFECTNotice of effectiveness6 Apr 2023
  • EFFECTNotice of effectiveness31 May 2022
  • EFFECTNotice of effectiveness6 Apr 2022
  • EFFECTNotice of effectiveness20 May 2021
  • EFFECTNotice of effectiveness8 Apr 2020
  • EFFECTNotice of effectiveness8 Apr 2020
  • EFFECTNotice of effectiveness11 Oct 2018
  • CT ORDERConfidential treatment order10 Jul 2018
  • EFFECTNotice of effectiveness4 May 2017
  • CT ORDERConfidential treatment order15 Mar 2017
  • EFFECTNotice of effectiveness16 Nov 2016
  • EFFECTNotice of effectiveness13 May 2016
  • CT ORDERConfidential treatment order11 May 2016
  • EFFECTNotice of effectiveness14 May 2015

Tender Offers And Going Private(2)

Expand
  • SC 13E3/AGoing private transaction statement (amendment)4 Aug 2015
  • SC 13E3Going private transaction statement2 Jun 2015

Exempt Offerings(6)

Expand
  • D06b30 Mar 2015
  • D06b2 Jan 2014
  • D/ANotice of exempt offering of securities (Reg D, amendment)8 Aug 2013
  • D/ANotice of exempt offering of securities (Reg D, amendment)31 Jul 2013
  • DNotice of exempt offering of securities (Reg D)10 Jul 2013
  • DNotice of exempt offering of securities (Reg D)25 Feb 2013

Other(9)

Expand
  • CERTNYSAUTO-GENERATED PAPER DOCUMENT18 Aug 2015
  • 25NOTIFICATION OF REMOVAL FROM LISTING24 Feb 2010
  • 10-K405FORM 10-K FOR FISCAL YEAR ENDED 12/31/200121 Mar 2002
  • 10-K405FORM 10-K FOR THE FISCAL YEAR ENDED 12/31/200019 Mar 2001
  • 10-K40510-K40510 Mar 1999
  • 10-K40510-K40531 Mar 1998
  • 10-K405/A10-K405/A25 Jun 1997
  • 10-K405/A10-K405/A16 Jun 1997
  • 10-K40510-K40517 Mar 1997

Financials & Metrics

FinancialsChartingShort InterestEmployees